Glenmark Pharma launches teneligliptin+dapagliflozin FDC for type-2 diabetes in India

20 Oct 2022 , 09:22 AM

Marketed under the brand name Zita D; it contains Teneligliptin (20mg) + Dapagliflozin (5 mg/10 mg), and must be taken once daily under prescription to improve glycemic control & prevent complications in adult patients with type 2 diabetes, especially the ones with comorbidities. Teneligliptin is a widely used DPP4i (dipeptidyl peptidase 4) inhibitor whereas Dapagliflozin is the most prescribed SGLT&8208;2i (sodium glucose co&8208;transporter 2) inhibitor for diabetic patients in the country. While Zita D is a promising treatment option in managing uncontrolled type-2 diabetes with co&8208;morbidities, this FDC has also proven to be effective among adult diabetic patients without comorbidities. According to IQVIA sales data for the 12&8208;month period ending Sept. 2022, the market for oral anti&8208;diabetic drugs in India is estimated to be Rs 11,796 crore with an annual growth of 7% against the corresponding period last year (MAT Sept. 2021). As per the International Diabetes Federation (IDF), the prevalence of diabetes in India is expected to increase to 125 million by 2045. Out of these, 77% of patients have uncontrolled diabetes. Moreover, about eight out of ten patients with diabetes also have one or more comorbidity in India. Glenmark Pharmaceuticals is a global pharmaceutical company with a presence across specialty, generics, and OTC businesses. The companys consolidated net profit declined 37.20% to Rs 192.53 crore on a 7.67% fall in sales to Rs 2,720.10 crore in Q1 FY23 over Q1 FY22. The scrip shed 0.10% to currently trade at Rs 395 on the BSE. Powered by Capital Market – Live News